Government ❯ Regulatory Agencies ❯ Food and Drug Administration

Drug Approval Process

Mifepristone Pediatric Drug Use Clinical Trials Psychedelic Therapies Controlled Substances New Drug Application Shortage Management Telehealth Policy Market Withdrawals Over-the-Counter Medications Clinical Protocol Reviews Conditional Drug Approval Safety Regulations Patient Advocacy Mifepristone Regulation Mifepristone Review Patient Safety Risk Evaluation and Mitigation Strategies Priority Review Mifepristone Study

FDA Launches Retrospective Safety Study of Mifepristone

The government is conducting a review that could narrow telehealth and mail access to the abortion pill and shape regulatory rules going forward.

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

FDA Grants Conditional Approval to Exzolt Cattle-CA1 for Screwworm and Cattle Fever Tick

FDA Adds Boxed Warning to Elevidys, Narrows Use to Ambulatory Patients 4 and Older

FDA Grants Accelerated Approval to Forzinity, First Therapy for Barth Syndrome

FDA launches AI assistant Elsa early as staff flag readiness issues